Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Adrian Cook"'
Autor:
R. Roux, C. Butcher, G. Bertelli, Rosemary Lord, R.M. Glasspool, Shibani Nicum, Adrian Cook, Michelle Ferguson, Melanie Mackean, M. Martinez, S. Love, L. Howells, Christina Fotopoulou, Eleni Frangou, Sarah P. Blagden, Nicholas J. Hulbert-Williams
Publikováno v:
Gynecologic Oncology. 162:431-439
Background Fear of disease progression (FOP) is a rational concern for women with Ovarian Cancer (OC) and depression is also common. To date there have been no randomized trials assessing the impact of psychological intervention on depression and FOP
Autor:
Timothy J. Perren, Rosemary Lord, Jane Hook, Ian A. McNeish, Christopher J. Poole, Jonathan A. Ledermann, Helena M. Earl, Sarah P. Blagden, Adrian Cook, Jae Weon Kim, Graham Dark, Andrew R Clamp, Marcia Hall, Dearbhaile M. O'Donnell, Richard Kaplan, Ian R. White, Lesley Howells, Andrew Dean, Elizabeth C. James
Publikováno v:
Lancet Oncol
The Lancet. Oncology
The Lancet. Oncology
Summary Background The ICON8 study reported no significant improvement in progression-free survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly treatment among patients with epithelial ovarian cancer. All ICON8 patie
Autor:
Hani Gabra, Dearbhaile M. O'Donnell, S. P. Stenning, Christopher Coyle, Jane Hook, Rosalind Glasspool, Graham Dark, Rachel Jones, Susana Banerjee, Jonathan A. Ledermann, Helena M. Earl, Andrew R Clamp, Adrian Cook, Marcia Hall, Timothy J. Perren, Sarah Williams, Rosemary Lord, Mahesh K. B. Parmar, Gosala S. Gopalakrishnan, Ann Marie Swart, Jae Weon Kim, Sudha Sundar, James D. Brenton, Elizabeth C. James, Raj Naik, Richard Kaplan, Iain A. McNeish, Andrew Dean, Sarah P. Blagden
Publikováno v:
Lancet (London, England)
Background:\ud Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a significant improvement in progression-free and overall survival with
Autor:
Andrew R Clamp, Sharadah Essapen, Adrian Cook, Marcia Hall, Elizabeth C. James, Sarah Williams, Jonathan A. Ledermann, Kate Scatchard, Jae Weon Kim, Jonathan Krell, Abel Zachariah, Gordon C Jayson, Iain A. McNeish, Axel Walther, Anjana Anand, Rachel Jones, Sudha Sundar, Christine Parkinson, Jeff Summers, Robert D. Morgan, Dolores Gallardo-Rincón, Christopher J. Poole, Graham Dark, Rosemary Lord, Rosalind Glasspool, Michelle Lockley
Publikováno v:
The Lancet. Oncology. 22(2)
Summary Background Platinum-based neoadjuvant chemotherapy followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced-stage epithelial ovarian cancer. Although this therapeutic approach has been vali
Autor:
Chee Goh, Peter Cooke, Anjali Zarkar, Holly Pickering, Noel W. Clarke, Julian Money-Kyrle, Henriette Lindberg, Wendy R. Parulekar, Klaus Brasso, Mahesh K. B. Parmar, Martin Andreas Røder, Jason F. Lester, S L Morris, Nicholas D. James, Amit Bahl, Rajendra Persad, William Cross, Stephanie Gibbs, Charles Catton, Henrik Jakobsen, Peter Ostler, Rakesh Raman, James M. Wilson, Ian Sayers, Matthew R. Sydes, Ramasamy Jaganathan, Heather Payne, Lisa Owen, Howard Kynaston, Joe M. O'Sullivan, Adrian Cook, Sandeep Gujral, Alvan Pope, Ben Eddy, Chris Parker, Matthew S. Simms, Juliette Anderson, Rick Popert, Prashant Patel, Alastair Henderson, David Bottomley, John P Logue, Peter Meidahl Petersen, Fred Saad, Kathryn Lees, Rohit Chahal, Catherine Heath, S.K. Sundaram
Publikováno v:
Lancet (London, England). 396(10260)
Summary Background The optimal timing of radiotherapy after radical prostatectomy for prostate cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy versus an observation policy with salvage radiotherapy for prosta
Autor:
Sara M. Debanne, Ying Jiang, Nigel Klein, Grace A. McComsey, Julia Kenny, Sahera Dirajlal-Fargo, Victor Musiime, Grace Mirembe, Adrian Cook
Publikováno v:
Pediatric Infectious Disease Journal. 36:761-767
Background Few studies have investigated metabolic complications in HIV-infected African children and their relation with inflammation. Methods We compared baseline and changes in insulin resistance [homeostatic model assessment of insulin resistance
Autor:
Jonathan A. Ledermann, Fharat A. Raja, Ann Marie Swart, Galina Velikova, Adrian Cook, Richard Kaplan, Julia Brown, Dan Stark, Wendi Qian, Michael Brundage, Andrew C. Embleton
Publikováno v:
Cancer. 123:2752-2761
BACKGROUND: The ICON6 trial showed that cediranib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, improved clinical outcomes for patients with platinum-sensitive relapsed ovarian cancer when it was used with chemothera
Autor:
Matthew R. Sydes, Noel W. Clarke, Fred Saad, Catherine Heath, H. Payne, Klaus Brasso, Adrian Cook, Henriette Lindberg, Chris Parker, Martin Andreas Røder, Anjali Zarkar, John P Logue, P. Meidahl Petersen, Charles Catton, M.K.B. Parmar, Howard Kynaston, Rajendra Persad, Rakesh Raman, W. Parulekar, William Cross
Publikováno v:
Annals of Oncology. 30:v883-v884
Background The optimal timing of RT after RP for prostate cancer (PCa) is uncertain. RADICALS-RT compared the efficacy and safety of adjuvant RT (aRT) versus an observation policy with salvage RT for PSA failure (Obs+sRT). Methods Patients with post-
Autor:
J-W. Kim, Jonathan A. Ledermann, Ann Marie Swart, C. Coyle, Andrew R Clamp, Timothy J. Perren, Dearbhaile M. O'Donnell, S. Blagden, Andrew Dean, Richard Kaplan, Iain A. McNeish, Mona Parmar, J. Badrock, Jane Hook, Sudha Sundar, Adrian Cook, D. Gallardo-Rincon, Elizabeth C. James, Raj Naik, James D. Brenton
Publikováno v:
Annals of Oncology. 31:S610
Autor:
AS Walker, Margaret J. Thomason, Moira J. Spyer, Adrian Cook, Patricia Nahirya-Ntege, Immaculate Nankya, Lincoln Mugarura, Diana M. Gibb, Bethany Naidoo-James, Emmanuel Ndashimye, Navdeep K. Thoofer, Victor Musiime, Tawanda Mhute, Marshall Munjoma, Wendy Snowden, Philip Kasirye
Publikováno v:
AIDS. 30:1761-1770
Background Antiretroviral therapy (ART) adherence is critical for successful HIV treatment outcomes. Once-daily dosing could improve adherence. Plasma concentrations of once-daily vs twice-daily abacavir + lamivudine are bioequivalent in children, bu